drugset / Trial / NCT05568706
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult subjects with confirmed RSV infection who are at high risk for complications after RSV infection.
Timeline
- Start
- 2022-11-29
- Primary completion
- 2025-06-23
- Completion
- 2025-06-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | zelicapavir | Small molecule | 800 mg | Oral |